SCHEMBL335045

SCHEMBL335045

CC(=O)c1cnoc1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL28353986 0.83 LMNA (0.50)
SCHEMBL439222 0.82
SCHEMBL29261172 0.80 LMNA (0.51)
SCHEMBL1023500 0.80
Hydrochloric Acid SCHEMBL5593733 0.80 LMNA (0.51)
SCHEMBL1374655 0.80
SCHEMBL13531134 0.80
Hydrochloric Acid SCHEMBL30684514 0.78 LMNA (0.46)
SCHEMBL28353985 0.78 LMNA (0.43)
SCHEMBL15822039 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613408-A Bicyclic ketone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2025-03-14 CN disclosed
CN-110914271-B Bicyclic ketone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2024-12-10 CN disclosed
US-20240300974-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2024-09-12 US disclosed
EP-4397309-A2 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2024-07-10 EP disclosed
EP-3652178-B1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2024-01-24 EP disclosed
US-11834461-B2 Bicyclic ketone compounds and methods of use thereof GENENTECH, INC. (US) 2023-12-05 US disclosed
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
US-20230065629-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-03-02 US disclosed
US-11591333-B2 Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors CINAKATE PHARM TECH (SHANGHAI) CO., LTD. (CN) 2023-02-28 US disclosed
US-20220017522-A1 METHOD FOR PREPARING PYRROLOPYRIMIDINE COMPOUND AND APPLICATION THEREOF CINKATE PHARMACEUTICAL INTERMEDIATES CO., LTD. (CN) 2022-01-20 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed
WO-2008055488-A1 MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS ZEDIRA GMBH (DE) 2008-05-15 WO disclosed
US-7176214-B2 Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-13 US disclosed
US-4499279-A ANTIDIABETIC AND HYPOGLYCEMIC AGENTS SANDOZ, INC. (US) 1985-02-12 US disclosed
US-4467096-A ANTIDIABETIC AGENTS, INTERMEDIATES THEREFOR SANDOZ, INC. (US) 1984-08-21 US disclosed
US-4421752-A ANTIDIABETIC AGENT SANDOZ, INC. (US) 1983-12-20 US disclosed
US-4419353-A ANTIDIABETIC AGENTS SANDOZ, INC. (US) 1983-12-06 US disclosed
US-4397850-A HYPOGLYCEMIC, ANTIDIABETIC SANDOZ, INC. (US) 1983-08-09 US disclosed
US-4336391-A ANTIDIABETIC AGENTS SANDOZ, INC. (US) 1982-06-22 US disclosed
US-4336379-A ANTIDIABETIC AGENTS SANDOZ, INC. (US) 1982-06-22 US disclosed